(Q37510861)

English

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics

scientific article published on July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics (English)

1 reference

Europe PubMed Central

20 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

drug metabolism

1 reference

based on heuristic

inferred from title

author name string

Leonid Gibiansky

1

1 reference

Europe PubMed Central

20 August 2017

Ekaterina Gibiansky

2

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

1 July 2009

1 reference

Europe PubMed Central

20 August 2017

Expert Opinion on Drug Metabolism & Toxicology

1 reference

Europe PubMed Central

20 August 2017

5

1 reference

Europe PubMed Central

20 August 2017

7

1 reference

Europe PubMed Central

20 August 2017

803-812

1 reference

Europe PubMed Central

20 August 2017

Pharmacologic target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Pharmacokinetic model of target-mediated disposition of thrombopoietin

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Target-mediated drug disposition and dynamics

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

1 reference

https://api.crossref.org/works/10.1517%2F17425250902992901

21 January 2018

Identifiers

10.1517/17425250902992901

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37510861&oldid=2164976836"